Nizze JA - Search Results

1

Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.

Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL. Barth A, et al. Among authors: nizze ja. Cancer Res. 1994 Jul 1;54(13):3342-5. Cancer Res. 1994. PMID: 8012946

2

Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.

Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM. Morton DL, et al. Among authors: nizze ja. Ann Surg. 2002 Oct;236(4):438-48; discussion 448-9. doi: 10.1097/00000658-200210000-00006. Ann Surg. 2002. PMID: 12368672 Free PMC article. Clinical Trial.

3

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, et al. Morton DL, et al. Among authors: nizze ja. Ann Surg. 1992 Oct;216(4):463-82. doi: 10.1097/00000658-199210000-00010. Ann Surg. 1992. PMID: 1417196 Free PMC article. Clinical Trial.

4

Active specific immunotherapy in malignant melanoma.

Morton DL, Foshag LJ, Nizze JA, Gupta RK, Famatiga E, Hoon DS, Irie RF. Morton DL, et al. Among authors: nizze ja. Semin Surg Oncol. 1989;5(6):420-5. doi: 10.1002/ssu.2980050608. Semin Surg Oncol. 1989. PMID: 2531908 Review.

5

Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma.

Morton DL, Hoon DS, Nizze JA, Foshag LJ, Famatiga E, Wanek LA, Chang C, Irie RF, Gupta RK, Elashoff R. Morton DL, et al. Among authors: nizze ja. Ann N Y Acad Sci. 1993 Aug 12;690:120-34. doi: 10.1111/j.1749-6632.1993.tb44002.x. Ann N Y Acad Sci. 1993. PMID: 8368731 Clinical Trial. No abstract available.

6

Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.

Jones RC, Kelley M, Gupta RK, Nizze JA, Yee R, Leopoldo Z, Qi K, Stern S, Morton DL. Jones RC, et al. Among authors: nizze ja. Ann Surg Oncol. 1996 Sep;3(5):437-45. doi: 10.1007/BF02305761. Ann Surg Oncol. 1996. PMID: 8876885

7

Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases.

Hsueh EC, Nathanson L, Foshag LJ, Essner R, Nizze JA, Stern SL, Morton DL. Hsueh EC, et al. Among authors: nizze ja. Cancer. 1999 May 15;85(10):2160-9. Cancer. 1999. PMID: 10326694 Clinical Trial.

8

Sequential evaluation of general immune competence in cancer patients: correlation with clinical course.

Eilber FR, Nizze JA, Morton DL. Eilber FR, et al. Among authors: nizze ja. Cancer. 1975 Mar;35(3):660-5. doi: 10.1002/1097-0142(197503)35:3<660::aid-cncr2820350319>3.0.co;2-x. Cancer. 1975. PMID: 234294

9

Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic.

Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Morton DL, et al. Among authors: nizze ja. Ann Surg. 1991 Oct;214(4):491-9; discussion 499-501. doi: 10.1097/00000658-199110000-00013. Ann Surg. 1991. PMID: 1953101 Free PMC article.

10

Prognostic significance of pregnancy in stage I melanoma.

Wong JH, Sterns EE, Kopald KH, Nizze JA, Morton DL. Wong JH, et al. Among authors: nizze ja. Arch Surg. 1989 Oct;124(10):1227-30; discussion 1230-1. doi: 10.1001/archsurg.1989.01410100133023. Arch Surg. 1989. PMID: 2802988

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters